

Attachment 5C:

NCI ADULT/PEDIATRIC CIRB APPLICATION FOR ANCILLARY STUDIES

OMB#: 0925 – xxxx Expiry Date: xx/xx/xxx STATEMENT OF CONFIDENTIALITY

Collection of this information is authorized under 42 USC 285a. Completion of this form is required as per the NCI CIRB Standard Operations Procedures based on 45 CFR 46.103 (b) (4). If you choose not to complete this form, you will not be able to participate in the CIRB. Data collected as part of the NCI CIRB review is private and protected by law. Under the provisions of Section 301d of the Public Health Service Act, no information that could permit identification of a participating individual may be released. All such information will be kept private under the Privacy Act and will be presented only in statistical or summary form.

NOTIFICATION TO RESPONDENT OF ESTIMATED BURDEN

Public reporting burden for this collection of information is estimated to average 2 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-xxxx*). Do not return the completed form to this address.

Version 02/19/10 Page 1 of 9



Version 02/19/10 Page 2 of 9



NCI ADULT/PEDIATRIC CIRB APPLICATION FOR ANCILLARY STUDIES

PART A GENERAL INFORMATION	
FORM COMPLETION DATE (Initial submission):	
DATE OF CURRENT REVISIONS TO FORM INFORMAT	TION:
COOPERATIVE GROUP:	
GROUP STUDY NUMBER: CTSU PROTOCOL: Yes	□ No
PROTOCOL VERSION AND DATE:	
STUDY TITLE:	
STUDY CHAIR	
Name:	
Title:	
Specialty:	
Site:	
Address:	
Phone Number:	
E-mail Address: FAX Number:	
STUDY CO-CHAIR	
Name:	
Title:	
Specialty:	
Site:	
Address:	
Phone Number:	

E-mail Address: FAX Number:

Version 02/19/10 Page 3 of 9



CONTACT PERSON (Person to contact about this application if Chair not available)

Name:

Title:

Specialty:

Site:

Address:

Phone Number:

E-mail Address:

FAX Number:

PLEASE NOTE: CIRB membership includes individuals who are not part of the oncology and/or the scientific community. Therefore, you must use <u>lay language</u> and define all terms unique to science when completing this form.

PART B SUMMARY OF STUDY

- 1. Briefly state the question that this study will answer (i.e. state the hypothesis):
- 2. Briefly describe the background research that has led to your hypothesis:
- 3. Briefly describe the study. (Include schema.)
- 4. How will the research design answer the hypothesis?
- 5. What significance will the new information gained from this study have?

PART C SUBJECTS

- 1. Number of subjects to be enrolled in the study:
- 2. What is the age range of eligible subjects?

If subjects under the age of 18 are eligible, an assent form must be attached.

Version 02/19/10 Page 4 of 9



3. Which of the following groups are eligible to be no. A "no" indicates that all persons in that ca		
Incompetent persons (excluding minors):	☐ Yes	□ No
(Incompetent persons include those who has those whose mental status prevents them for consent and making decisions [such as those Alzheimer's disease]).	rom understandiı	
Women of reproductive potential: Pregnant women: Men of reproductive potential: Minorities: Prisoners:	 ☐ Yes ☐ Yes ☐ Yes ☐ Yes ☐ Yes 	 □ No □ No □ No □ No □ No
Explanation of Exclusion		
Federal IRB regulations require equitable sele policy requires that minorities and women be research subjects. If you checked "no" to any provide a scientific reason for such exclusion:	adequately repre	sented as
4. Will the subject have specimens collected that v standard care? (Either type or amount) Ye If yes, describe the means by which these speciments	s No	-
5. Will the subject have to make extra visits for sp	ecimen collection	?
If yes, a) Number of visits: b) Frequency of visits: c) Duration of visits:		
6. Will the subjects bear any costs that are not a p	oart of routine clin	nical care:
If yes, explain:		
a) Please list the relevant tests, procedures, ho	spitalizations, etc	, for which they

Version 02/19/10 Page 5 of 9



b) Are there means of subsidizing these extra costs for subjects who cannot afford them? \square Yes \square No
If yes, explain:
PART D RISKS, BENEFITS AND ALTERNATIVES
1. Describe any reasonably foreseeable risks or discomforts to the patient. Describe the frequency and complications associated with each.
2. Discuss measures taken to minimize risks.
3. How do you justify the risks inherent in participating in the study?
4. Describe any benefits to the subject or to others, which may be expected from the research (personal, social, scientific, etc.).
PART E GENETIC RESEARCH
Does this study include genetic research on samples or tissues?* \square Yes \square No If no, go to Part F.
*Human genetic research involves the study of inherited human traits. Much of this research is aimed at identifying DNA mutations that can help cause specific health problems, developing methods of identifying those mutations in patients, and improving the interventions available to help patients address those problems. Such research includes a) the analysis of human chromosomes or DNA from an individual and/or family members for the purpose of deriving information concerning the individual or family about the presence, absence, or mutation of genes, DNA markers, gene products or inherited characteristics or b) biochemical measurements of proteins and metabolites with the INTENT of collecting and evaluating information about heritable diseases and/or characteristics within a family.
If yes:
a) Why is this patient population appropriate for genetic research?
b) Will results be disclosed to the subjects? \square Yes \square No

Version 02/19/10 Page 6 of 9



If yes, describe in what way:

c) Will subjects be given the option of not receiving information about themselves?
d) Will the possible psychological and social risks of genetic research be adequately considered in the consent process? Will appropriate counseling be provided, both as part of the consent process and also when communicating test or other research results to subjects? Please explain.
e) Will subjects be informed about the possibility of incidental findings?
f) Will the data be protected from disclosure to third parties, such as employers and insurance companies? Describe confidentiality measures.
g) Will research findings be disclosed to subjects' physicians for clinical use? Will this plan be discussed with the subjects and their consent obtained?
h) Will vulnerable populations be adequately protected? $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$
If yes, how?
i) What provisions have been made for protecting against misuse of tissue samples?
j) What provisions have been made for the treatment of data and tissue samples in the event of subject withdrawal from study?
k) Describe ways that subject's privacy and confidentiality will be protected when publications are planned.
PART F STORAGE OF SPECIMENS FOR UNSPECIFIED FUTURE RESEARCH STUDIES
Does this study involve collection of specimens for unspecified future research studies? \square Yes \square No If no, go to PART G.
If yes:

Version 02/19/10 Page 7 of 9



a) What are the types and amounts of specimens to be collected? Justify the types and amounts.
b) Will you maintain identifying information or links to identifiers?
c) What information will be recorded?
d) Where will the tissue be stored?
e) For what types of research do you anticipate using the samples in the future?
f) Who will be responsible for distributing the tissue?
g) What steps will be taken to protect confidentiality?
h) What arrangements will you make with the clinical laboratories to guarantee that all clinically indicated procedures are completed?
PART G FINANCIAL CONFLICT OF INTEREST
Definition: A financial conflict of interest exists or may appear to exist when a person has an economic interest in, receives funding or compensation from (for speaker's bureaus, advisory boards, research support, etc.), or acts as an officer of or a consultant to any organization or company whose financial interests would reasonably appear to be affected by this research.
1. Does any person who has a substantial role in: a) the decision about whether or not the study should be done; b) the design of the study; or c) the analysis or the management of the data from the study, have a financial conflict of interest or the appearance of a financial conflict of interest as defined above? \square Yes \square No
If yes, please explain.

Version 02/19/10 Page 8 of 9



2. Does any person as described in question #1 have a family member (spouse or dependent child) who has a financial interest in the study? \square Yes \square No
If yes, please explain.
3. Do individual investigators or sites receive additional funding for patient accrual to this study beyond that provided by the NCI? \square Yes \square No If yes, please explain.

PART H INFORMED CONSENT

Please attach a copy of the informed consent form for this protocol to this application form.

Please note: A Word or Word Perfect file containing the informed consent form(s) must also be emailed to the CIRB Project Office in order for this application to be considered complete.

Kindly send the CIRB application and the consent document in care of CIRB Contact at ncicirbcontact@emmes.com. Thank you!

Version 02/19/10 Page 9 of 9